Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BMS' Opdivo Gets CHMP Backing For Expanded European Label

This article was originally published in The Pink Sheet Daily

Executive Summary

Use for previously treated advanced renal cell carcinoma in adults as well as previously treated metastatic non-squamous non-small cell lung cancer, regardless of PD-L1 expression, is recommended by EMA Committee for Medicinal Products for Human Use.

You may also be interested in...

Deal Watch: Exelixis Teams With Ipsen For Ex-US Commercialization Of RCC Candidate

Onxeo acquires signal-interfering DNA repair technology for its orphan oncology focus. Sanofi returns auto-injector product to kaleo after product recall.

AstraZeneca’s Durvalumab/Tremelimumab Combo Holds Its Own In NSCLC

Phase Ib results for PD-L1/CTLA-4 combination look competitive, but editorial questions whether the company has moved too fast with development in response to intense market pressure.

PD-1 Round-Up: Bristol's Lead Grows, But Field Could Soon See Major Change

Leading sponsors of PD-1/L1 checkpoint inhibitors looked back on a string of successes and ahead toward the future for combinations with a wide range of other targets during full-year earnings calls.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts